THERAPY DOSSIER · th-9c6576c15916

(-)-Epicatechin

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL583912 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: (-)-epicatechin; Epicatechin; Epicatechol; L-epicatechin; NSC-81161
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01690676 ↗PHASE2completed

Apple polyphenol extract rich in epicatechin on brachial artery FMD

Borderline Hypertension

Enrolment: 57 · Results not recorded

NCT02656212 ↗PHASE1completed

Pre-clinical and initial clinical research on epicatechin (Part 2)

Pre-diabetes

Enrolment: 15 · Results not recorded

NCT02898571 ↗NAunknown

Effects of antioxidant drinks (vitamin C and epicatechin) on antioxidant capacity

Vitamin C and Epicatechin antioxidant capacity

Enrolment: 10 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31234659 ↗2019Reported benefit

(-)-Epicatechin mitigates radiation-induced intestinal injury and promotes intestinal regeneration via suppressing oxidative stress.

MouseRadiationC57BL/6 and Lgr5-EGFP-IRES-creERT2Male

Model: Ionising radiation-induced intestinal epithelial injury, with an injured intestinal organoid (minigut) model

Epicatechin suppressed oxidative stress, reduced crypt cell apoptosis, enhanced Lgr5 stem cell activity and promoted intestinal epithelial regeneration after irradiation via Nrf2 and Wnt/beta-catenin signalling.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…